Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Tyagi

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2002
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigHDeepak Kaushal, Benjamin G Schroeder, Sandeep Tyagi, et al.
The Indian Journal of Medical Research|January 5, 2013
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovisZahoor Ahmad, Sandeep Tyagi, Austin Minkowsk, et al.
Chemistry & Biology|February 10, 2010
Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targetsOmonike Olaleye, Tirumalai R Raghunand, Shridhar Bhat, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of TuberculosisRokeya Tasneen, Fabrice Betoudji, Sandeep Tyagi, et al.
Antimicrobial Agents and Chemotherapy|December 9, 2024
Contribution of telacebec to novel drug regimens in a murine tuberculosis modelOliver D Komm, Sandeep Tyagi, Andrew Garcia, et al.
Plos Medicine|December 21, 2007
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine modelIan M Rosenthal, Ming Zhang, Kathy N Williams, et al.
The Journal of Infectious Diseases|February 17, 2025
Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine ModelsBernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, et al.
Infection and Immunity|February 24, 2004
Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysisDeborah E Geiman, Deepak Kaushal, Chiew Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamideJacques Grosset, Deepak Almeida, Paul J Converse, et al.
Infection and Immunity|February 24, 2004
Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbitsSusan E Dorman, Christine L Hatem, Sandeep Tyagi, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2002
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigHDeepak Kaushal, Benjamin G Schroeder, Sandeep Tyagi, et al.
The Indian Journal of Medical Research|January 5, 2013
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovisZahoor Ahmad, Sandeep Tyagi, Austin Minkowsk, et al.
Chemistry & Biology|February 10, 2010
Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targetsOmonike Olaleye, Tirumalai R Raghunand, Shridhar Bhat, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of TuberculosisRokeya Tasneen, Fabrice Betoudji, Sandeep Tyagi, et al.
Antimicrobial Agents and Chemotherapy|December 9, 2024
Contribution of telacebec to novel drug regimens in a murine tuberculosis modelOliver D Komm, Sandeep Tyagi, Andrew Garcia, et al.
Plos Medicine|December 21, 2007
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine modelIan M Rosenthal, Ming Zhang, Kathy N Williams, et al.
The Journal of Infectious Diseases|February 17, 2025
Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine ModelsBernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, et al.
Infection and Immunity|February 24, 2004
Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysisDeborah E Geiman, Deepak Kaushal, Chiew Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamideJacques Grosset, Deepak Almeida, Paul J Converse, et al.
Infection and Immunity|February 24, 2004
Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbitsSusan E Dorman, Christine L Hatem, Sandeep Tyagi, et al.
Pageof 8